Summary
Reports of BRCA2 genetic mutations on the prognosis of familial breast cancer (BC) patients have been contradictory. True difference in survival, if it exists, would have important implications for genetic counseling and in treatment of hereditary BC. The purpose of this study was to compare overall survival rate (OSR) among BRCA2 mutation carriers, non-carriers and sporadic BC patients. We searched the PUBMED and EMBASE databases and retrieved 4529 articles using keywords that included breast cancer, BRCA, prognosis and survival. Nine articles were selected for systematic review and among them 6 were included in our meta-analysis. We used the fixed and random effect models to calculate the summary odds ratio (OR) and corresponding 95% confidence interval (CI). BRCA2 mutation carriers had significantly higher long-term OSR than non-carriers (OR=0.69 [95% CI=0.5–0.95]), while both short-term and long-term OSR of BRCA2 mutation carriers did not differ from those of patients with sporadic disease (OR=1.11 [95% CI=0.74–1.65]; 0.85 [95% CI=0.38–1.94], respectively). For BC-specific survival rate (BCSSR), BRCA2 mutation carriers had a similar BCSSR to the non-carriers (OR=0.61 [95% CI=0.28–1.34]). There was no significant difference in disease-free survival (DFS) between BRCA2 mutation carriers and patients with sporadic disease. Our results suggest that BRCA2 mutation increases long-term OSR in hereditary BC, which reminds us a new prospect of management of the disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science, 1994,265(5181):2088–2090
Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet, 1996,12(3):333–337
Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature, 1995,378(6559):789–792
Stratton MR, Ford D, Neuhasen S, et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet, 1994,7(1):103–107
Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst, 1998,90(15):1138–1145
Phillips KA. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol, 2000,18:107S–112S
Agnarsson BA, Jonasson JG, Bjornsdottir IB, et al. Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat, 1998,47(2): 121–127
Verhoog LC, Berns EM, Brekelmans CT, et al. Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol, 2000,18(21 Suppl):119S–124S
Armakolas A, Ladopoulou A, Konstantopoulou I, et al. BRCA2 gene mutations in Greek patients with familial breast cancer. Hum Mutat, 2002,19(1):81–82
Phillips KA, Andrulis IL, Goodwin PJ. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? J Clin Oncol, 1999,17 (11):3653–3663
Gaffney DK, Brohet RM, Lewis CM, et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol, 1998,47(2):129–136
Lee JS, Wacholder S, Struewing JP, et al. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst, 1999,91(3):259–263
Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol, 1999,17(11):3396–3402
Loman N, Johannsson O, Bendahl P, et al. Prognosis and clinical presentation of BRCA2-associated breast cancer. Eur J Cancer, 2000,36(11):1365–1373
Brekelmans CTM, Tilanus-Linthorst MMA, Seynaeve C, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer, 2007,43(5): 867–876
Eerola H, Vahteristo P, Sarantaus, L, et al. Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: A relative survival analysis from Finland. Int J Cancer, 2001,93(3):368–372
Goodwin PJ, Phillips KA, West DW, et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: An international prospective breast cancer family registry population-based cohort study. J Clin Oncol, 2012,30(1):19–26
Loman N, Johannsson O, Bendahl, P, et al. Prognosis and clinical presentation of BRCA2-associated breast cancer. Eur J Cancer, 2000,36(11):1365–1373
Moller P, Evans DG, Reis MM, et al. Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer, 2007,121(5): 1017–1020
Syamala V, Syamala VS, Sreeja L, et al. Hereditary breast/ovarian cancer: Clinicopathological characteristics and survival of BRCA2 positive and negative cases. J Exp Ther Oncol, 2008,7(3):227–236
Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet, 2010,376(9737):245–251
Kortmann U, McAlpine JN, Xue H, et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res, 2011,17(4):783–791
Morris SR, Carey LA. Gene expression profiling in breast cancer. Curr Opin Oncol, 2007,19(6):547–551
Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med, 2009,361(2):123–134
Kummar S, Chen A, Ji J, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res, 2011,71(17):5626–5634
Author information
Authors and Affiliations
Corresponding authors
Additional information
The authors contributed equally to this work.
Rights and permissions
About this article
Cite this article
Shao, J., Yang, J., Wang, Jn. et al. Effect of BRCA2 mutation on familial breast cancer survival: A systematic review and meta-analysis. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 35, 629–634 (2015). https://doi.org/10.1007/s11596-015-1481-7
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-015-1481-7